ArticlemAbs

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies.

Yizhou Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.